CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Does the media prefer CASI or ANRO?

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Alto Neuroscience. CASI Pharmaceuticals' average media sentiment score of 1.89 beat Alto Neuroscience's score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CASI Pharmaceuticals	Very Positive
Alto Neuroscience	Neutral

Do institutionals and insiders hold more shares of CASI or ANRO?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has stronger earnings and valuation, CASI or ANRO?

CASI Pharmaceuticals has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	0.56	-$39.26M	-$2.55	-0.51
Alto Neuroscience	N/A	N/A	-$61.43M	-$2.34	-1.10

Which has more risk & volatility, CASI or ANRO?

CASI Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Do analysts rate CASI or ANRO?

CASI Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 207.69%. Alto Neuroscience has a consensus price target of $8.50, suggesting a potential upside of 229.46%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alto Neuroscience	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Is CASI or ANRO more profitable?

Alto Neuroscience has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. Alto Neuroscience's return on equity of -39.35% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-129.05%	-972.55%	-77.33%
Alto Neuroscience	N/A	-39.35%	-33.86%

Summary

CASI Pharmaceuticals beats Alto Neuroscience on 8 of the 15 factors compared between the two stocks.